|
1
|
McCarthy M: US melanoma prevalence has
doubled over past 30 years. BMJ. 350:h30742015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rebecca VW, Somasundaram R and Herlyn M:
Pre-clinical modeling of cutaneous melanoma. Nat Commun.
11:28582020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long GV, Grob JJ, Nathan P, Ribas A,
Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT and
Davies MA: Factors predictive of response, disease progression, and
overall survival after dabrafenib and trametinib combination
treatment: A pooled analysis of individual patient data from
randomised trials. Lancet Oncol. 17:1743–1754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garbe C, Peris K, Hauschild A, Saiag P,
Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J,
Stratigos AJ, et al: Diagnosis and treatment of melanoma. European
consensus-based interdisciplinary guideline-Update 2016 = Eur J
Cancer. 63:201–217. 2016.PubMed/NCBI
|
|
6
|
Luther C, Swami U, Zhang J, Milhem M and
Zakharia Y: Advanced stage melanoma therapies: Detailing the
present and exploring the future. Crit Rev Oncol Hematol.
133:99–111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang Y, Song X, Li Y, Chen B, Zhao W,
Wang L, Zhang H, Liu Y, Han D, Zhang N, et al: LncRNA BCRT1
promotes breast cancer progression by targeting miR-1303/PTBP3
axis. Mol Cancer. 19:852020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu X, Zheng H, Tse G, Zhang L and Wu WKK:
CASC2: An emerging tumour-suppressing long noncoding RNA in human
cancers and melanoma. Cell Prolif. 51:e125062018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu W, Yan Z, Hu F, Wei W, Yang C and Sun
Z: Long non-coding RNA GAS5 accelerates oxidative stress in
melanoma cells by rescuing EZH2-mediated CDKN1C downregulation.
Cancer Cell Int. 20:1162020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu X, Zheng H, Tse G, Chan MT and Wu WK:
Long non-coding RNAs in melanoma. Cell Prolif. 51:e124572018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Richtig G, Ehall B, Richtig E,
Aigelsreiter A, Gutschner T and Pichler M: Function and clinical
implications of long Non-Coding RNAs in melanoma. Int J Mol Sci.
18:7152017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riefolo M, Porcellini E, Dika E,
Broseghini E and Ferracin M: Interplay between small and long
non-coding RNAs in cutaneous melanoma: A complex jigsaw puzzle with
missing pieces. Mol Oncol. 13:74–98. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leucci E, Vendramin R, Spinazzi M,
Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli
C, Vanderheyden K, et al: Melanoma addiction to the long non-coding
RNA SAMMSON. Nature. 531:518–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu K, Wang Q, Liu YL, Xiang Z, Wang QQ,
Yin L and Liu SL: LncRNA POU3F3 contributes to dacarbazine
resistance of human melanoma through the MiR-650/MGMT Axis. Front
Oncol. 11:6436132021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Attrill GH, Ferguson PM, Palendira U, Long
GV, Wilmott JS and Scolyer RA: The tumour immune landscape and its
implications in cutaneous melanoma. Pigment Cell Melanoma Res.
34:529–549. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu M, Fu P, Qu L, Liu J and Lin A: Long
noncoding RNAs, new critical regulators in cancer immunity. Front
Oncol. 10:5509872020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang K, Zhang L, Mi Y, Tang Y, Ren F, Liu
B, Zhang Y and Zheng P: A ceRNA network and a potential regulatory
axis in gastric cancer with different degrees of immune cell
infiltration. Cancer Sci. 111:4041–4050. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li G, Kryczek I, Nam J, Li X, Li S, Li J,
Wei S, Grove S, Vatan L, Zhou J, et al: LIMIT is an immunogenic
lncRNA in cancer immunity and immunotherapy. Nat Cell Biol.
23:526–537. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Appelbaum EN, Gross ND, Diab A, Bishop AJ,
Nader ME and Gidley PW: Melanoma of the external auditory canal: A
review of seven cases at a tertiary care referral center.
Laryngoscope. 131:165–172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bindea G, Mlecnik B, Tosolini M,
Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T,
Lafontaine L, Berger A, et al: Spatiotemporal dynamics of
intratumoral immune cells reveal the immune landscape in human
cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leucci E, Coe EA, Marine JC and Vance KW:
The emerging role of long non-coding RNAs in cutaneous melanoma.
Pigment Cell Melanoma Res. 29:619–626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma W, Qiao J, Zhou J, Gu L and Deng D:
Characterization of novel LncRNA P14AS as a protector of ANRIL
through AUF1 binding in human cells. Mol Cancer. 19:422020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vishnubalaji R, Shaath H, Elkord E and
Alajez NM: Long non-coding RNA (lncRNA) transcriptional landscape
in breast cancer identifies LINC01614 as non-favorable prognostic
biomarker regulated by TGFbeta and focal adhesion kinase (FAK)
signaling. Cell Death Discov. 5:1092019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dunn GP, Koebel CM and Schreiber RD:
Interferons, immunity and cancer immunoediting. Nat Rev Immunol.
6:836–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
von Locquenghien M, Rozalen C and
Celia-Terrassa T: Interferons in cancer immunoediting: Sculpting
metastasis and immunotherapy response. J Clin Invest.
131:e1432962021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alavi S, Stewart AJ, Kefford RF, Lim SY,
Shklovskaya E and Rizos H: Interferon signaling is frequently
downregulated in melanoma. Front Immunol. 9:14142018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 19:1189–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin JX and Leonard WJ: The role of Stat5a
and Stat5b in signaling by IL-2 family cytokines. Oncogene.
19:2566–2576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z,
Zhang Y, Liu R, Yao H and Song E: Association of long noncoding RNA
biomarkers with clinical immune subtype and prediction of
immunotherapy response in patients with cancer. JAMA Netw Open.
3:e2021492020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen M, Pan X, Gao Y, Ye H, Zhang J, Chen
Y, Pan M, Huang W, Xu X, Zhan Y and Jin L: LncRNA CRNDE exacerbates
IgA nephropathy progression by promoting NLRP3 inflammasome
activation in macrophages. Immunol Invest. 7:1–13. 2021. View Article : Google Scholar
|
|
37
|
Ladányi A: Prognostic and predictive
significance of immune cells infiltrating cutaneous melanoma.
Pigment Cell Melanoma Res. 28:490–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ladányi A, Kiss J, Somlai B, Gilde K,
Fejos Z, Mohos A, Gaudi I and Tímár J: Density of DC-LAMP(+) mature
dendritic cells in combination with activated T lymphocytes
infiltrating primary cutaneous melanoma is a strong independent
prognostic factor. Cancer Immunol Immunother. 56:1459–1469. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kobayashi T, Hamaguchi Y, Hasegawa M,
Fujimoto M, Takehara K and Matsushita T: B cells promote tumor
immunity against B16F10 melanoma. Am J Pathol. 184:3120–3129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garg K, Maurer M, Griss J, Brüggen MC,
Wolf IH, Wagner C, Willi N, Mertz KD and Wagner SN:
Tumor-associated B cells in cutaneous primary melanoma and improved
clinical outcome. Hum Pathol. 54:157–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Monti M, Consoli F, Vescovi R, Bugatti M
and Vermi W: Human plasmacytoid dendritic cells and cutaneous
melanoma. Cells. 9:4172020. View Article : Google Scholar : PubMed/NCBI
|
